Arabic Arabic English English French French German German
dark

TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”) an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $25,000,000 Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections

Next Post

What is the evidence on how to improve older adults’ functional abilities at home?

Related Posts
Total
0
Share